European Commission Approves Tislelizumab for Three Indications in Non-Small Cell Lung Cancer

In Brief for November 8, 2023

Regulatory Approval Brings New Targeted Treatment Option for NSCLC to European Union

US Approves Osimertinib with Chemotherapy for EGFR+ NSCLC; Approvals Pending in Other Countries

US FDA Approves Frontline Amivantamab Combination for Patients with EGFR exon 20 Insertion-mutated NSCLC

Regulating Artificial Intelligence

US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR

US Food and Drug Administration Accepts New Drug Application for Ensartinib

Regulatory News for April 24, 2024

ALINA Trial Leads to New Treatment Option for Early-Stage ALK+ NSCLC

Stark Contrast in Recent Tobacco Control Laws Worldwide

European Commission OKs Tislelizumab for NSCLC